Cancerify Logo
Log inSign up
Back to clinical trials
RecruitingInterventionalPhase 2

A Phase II Study of Ipilimumab, Cabozantinib, and Nivolumab in Rare Genitourinary Cancers (ICONIC)

NCT ID: NCT03866382Sponsor: National Cancer Institute (NCI)Last updated: 2026-06-18

Summary

This phase II trial studies how well cabozantinib works in combination with nivolumab and ipilimumab in treating patients with rare genitourinary (GU) tumors that has spread from where it first started (primary site) to other places in the body. Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving cabozantinib, nivolumab, and ipilimumab may work better in treating patients with genitourinary tumors that have no treatment options compared to giving cabozantinib, nivolumab, or ipilimumab alone.

Detailed description

PRIMARY OBJECTIVE: I. To evaluate the efficacy of cabozantinib s-malate (cabozantinib) combined with nivolumab and ipilimumab in the first or second-line (and beyond) setting for patients within each of the rare genitourinary (GU) variant histology group of interest, as measured by objective response rate (ORR). SECONDARY OBJECTIVES: I. To estimate the progression-free survival (PFS) for patients treated with cabozantinib combined with nivolumab and ipilimumab within each rare variant histology. II. To estimate the overall survival (OS) for patients treated with cabozantinib combined with nivolumab and ipilimumab within each rare variant histology. III. To estimate the clinical benefit rate (defined as complete response \[CR\] or partial response \[PR\] or stable disease \[SD\]) for patients treated with cabozantinib combined with nivolumab and ipilimumab within each rare variant histology. IV. To assess the safety of treating patients with rare variant histologies with cabozantinib combined with nivolumab and ipilimumab. V. To support tissue banking and collection of clinical follow-up data for GU tract rare histological variants. EXPLORATORY OBJECTIVE: I. To assess effects of treatment in patients with bone-only disease by bone scan. OUTLINE: Patients receive cabozantinib orally (PO) once daily (QD) on days 1-21 of cycles 1-4 and on days 1-28 of subsequent cycles. Patients also receive nivolumab intravenously (IV) over 30 minutes on day 1 and ipilimumab IV over 90 minutes on day 1 of cycles 1-4. Patients then receive nivolumab IV over 30 minutes on day 1 of subsequent cycles. Treatment repeats every 21 days for cycles 1-4 and every 28 days for subsequent cycles for 2 years in the absence of disease progression or unacceptable toxicity. Patients may undergo echocardiography during screening and undergo computed tomography (CT) or magnetic resonance imaging (MRI), bone scan and blood and urine sample collection throughout the trial and may undergo positron emission tomography (PET)/CT throughout the trial. After completion of study treatment, patients are followed up every 2 months for up to 5 years.

Arms & interventions

  • ProcedureBiospecimen Collection

    Undergo blood and urine sample collection

  • ProcedureBone Scan

    Undergo bone scan

  • DrugCabozantinib S-malate

    Given PO

  • ProcedureComputed Tomography

    Undergo CT and/or PET/CT scan

  • ProcedureEchocardiography Test

    Undergo echocardiography

  • BiologicalIpilimumab

    Given IV

  • ProcedureMagnetic Resonance Imaging

    Undergo MRI

  • BiologicalNivolumab

    Given IV

  • ProcedurePositron Emission Tomography

    Undergo PET/CT scan

Outcome measures

Primary

  • Objective response rate (ORR)

    An objective response is defined as a confirmed complete response (CR) or partial response (PR) as assessed by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. A confirmed tumor response is defined to be either a CR or PR noted as the objective status on 2 consecutive evaluations at least 4 weeks apart. Will be estimated by the number of confirmed objective responses divided by the total number of evaluable patients. Confidence intervals for the true ORR will be calculated.

    Time frame: Up to 5 years

Secondary

  • Duration of response

    Time frame: From time measurement criteria are met for CR or PR (whichever is first recorded) until the first date that recurrent or progressive disease is objectively documented, assessed up to 5 years

  • Progression-free survival (PFS)

    Time frame: From start of treatment to time of progression or death, whichever occurs first, assessed up to 5 years

  • Overall survival

    Time frame: Up to 5 years

  • Clinical benefit rate (CBR)

    Time frame: Up to 5 years

  • Incidence of adverse events (AE)

    Time frame: Up to 5 years

Eligibility criteria

Sex: AllAge: 18 Years and olderHealthy volunteers: No
Inclusion Criteria: * Metastatic disease defined as new or progressive lesions on cross-sectional imaging or bone scan. Patients must have at least: * One measurable site of disease as per Response Evaluation Criteria in Solid Tumors (RECIST) version (v) 1.1 * One bone lesion on bone scan (tec99 or sodium fluoride \[NaF\] PET/CT, CT or MRI) for the bone-only cohort. * Histologically confirmed diagnosis of one of the following metastatic cohorts: * Small cell/ neuroendocrine carcinoma of the bladder (Cohort A)- All urothelial carcinomas with any amount of neuroendocrine differentiation (including small cell differentiation) will be included. If the tumor is purely neuroendocrine, metastasis from another site of origin should be clinically excluded * Adenocarcinoma of the bladder, or urachal adenocarcinoma, or bladder/urethra clear cell adenocarcinoma (Cohort B) - must be pure (per World Health Organization \[WHO\] definition), (i.e. urothelial carcinoma with glandular differentiation is not considered a pure adenocarcinoma * Squamous cell carcinoma of the bladder (Cohort C) - must be pure (i.e. urothelial carcinoma with squamous differentiation is not considered a pure squamous cell carcinoma) * Plasmacytoid urothelial carcinoma (Cohort D) - Tumor should show predominantly \> or equal \~ 50% plasmacytoid histology (including all types of discohesive growth, such as tumors with signet-ring and/or rhabdoid features as well) * Any penile cancer (Cohort E) * Sarcomatoid renal cell carcinoma (Cohort F) - Tumor should be predominantly sarcomatoid \~ 50% (including rhabdoid differentiation) is also unclassified renal cell carcinomas (RCCs): all (assuming they are high grade with metastasis) malignant angiomyolipomas are allowed * Other miscellaneous histologic variants of the urothelial carcinoma, such as, but not limited to (Cohort G) : Micropapillary (Tumor should show predominantly \> or equal 50% micropapillary architecture), giant cell, lipid-rich, clear cell and nested variants (Tumor should predominantly \> or equal 50% show these features), large cell neuroendocrine carcinoma, lymphoepithelioma-like carcinoma and mixed patterns will be considered, as well as small cell neuroendocrine prostate cancer (Only treatment-naïve primary small cell of prostate with any amount of small cell component allowed. Post-treatment small cell prostatic carcinomas are not allowed), Malignant testicular Sertoli or Leydig cell tumors, and papillary and chromophobe RCC * Note: Translocation positive renal cell carcinoma patients are eligible. However, AREN1721 should be considered before this trial * Sarcomatoid urothelial carcinoma (Cohort H) - Tumor should show predominantly \~ 50% sarcomatoid differentiation * Renal medullary carcinoma (Cohort I) - Per World Health Organization (WHO) definition, ideally confirmed with immunostains * Bone-only metastatic GU tumors (non-prostate) (Cohort J) - All genitourinary histologies, except prostate are eligible * Renal Collecting Duct Carcinoma (Cohort K) - Per WHO definition (medullary involvement, predominant tubular morphology, desmoplastic stromal reaction, high grade cytology, infiltrative growth pattern, and absence of other renal cell carcinoma subtype or urothelial carcinoma) * Urethra carcinoma (Cohort L) - May be of any histology but if urothelial carcinoma then must be isolated to the urethra and not have metachronous or synchronous urothelial carcinoma of the bladder * H\&E slides from diagnostic tumor tissue for retrospective central pathology review * Patients may have received up to 2 systemic anti-cancer treatments or be treatment naive. Patients with small cell carcinoma should have received a platinum-based combination regimen either as neoadjuvant, adjuvant or first-line treatment). Patients in the bone-only cohort may be urothelial carcinoma histology but must receive standard cisplatin-based chemotherapy (if cisplatin-eligible) * Age \>= 18 years * Patients must be able to swallow oral formulation of the tablets * Karnofsky performance status \>= 80% * Absolute neutrophil count (ANC) \>= 1,000/mcL * Platelet count \>= 75,000/mcL * Total bilirubin =\< 1.5 x upper limit of normal (ULN). For subjects with known Gilbert's disease or similar syndrome with slow conjugation of bilirubin, total bilirubin =\< 3.0 mg/dL * Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =\< 3.0 x institutional upper limit of normal (ULN) (or =\< 5 x ULN for patients with liver metastases or Gilbert's disease) * Creatinine =\< 1.5 x upper limit of normal (ULN) OR creatinine clearance \>= 40 mL/min/1.73 m\^2 (calculated using the Chronic Kidney Disease Epidemiology \[CKD-EPI\] equation or Cockcroft-Gault formula) for patients with creatinine levels above institutional normal * Hemoglobin \>= 9 g/dL (transfusion of packed red blood cells \[PRBCs\] allowed) * Serum albumin \>= 3.2 g/dL * Lipase and amylase =\< 2.0 x ULN and no radiologic (on baseline anatomical imaging) or clinical evidence of pancreatitis * Prior treatment with MET or VEGFR inhibitors is allowed. However, prior cabozantinib will not be allowed. Also, patients that have received both prior MET or VEGF and prior PD-1/PD-L1/CTLA-4 (sequentially or in combination) are also not allowed * No prior treatment with any therapy on the PD-1/PD-L1 axis or anti- CTLA-4/CTLA-4 inhibitors with the exception of patients with "urothelial carcinoma" histology (cohorts D, H, J, L) * Human immunodeficiency virus (HIV)-positive patients are eligible if on stable dose of highly active antiretroviral therapy (HAART), no clinically significant drug-drug interactions are anticipated with the current HAART regimen, CD4 counts are greater than 350 and viral load is undetectable * Patients with rheumatoid arthritis and other rheumatologic arthropathies, Sjogren's syndrome and psoriasis controlled with topical medication only and patients with positive serology, such as antinuclear antibodies (ANA), anti-thyroid antibodies etc. are eligible but should be considered for rheumatologic evaluation for the presence of target organ involvement and potential need for systemic treatment * Patients with vitiligo, endocrine deficiencies including thyroiditis managed with replacement hormones or medications (e.g. thyroiditis managed with propylthiouracil \[PTU\] or methimazole) including physiologic oral corticosteroids are eligible * Patients who have evidence of active or acute diverticulitis, intra-abdominal abscess, and gastrointestinal (GI) obstruction, within 12 months are not eligible * Women of childbearing potential must have a negative pregnancy test =\< 7 days prior to registration * Women of childbearing potential include women who have experienced menarche and who have not undergone successful surgical sterilization (hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) or are not postmenopausal. Post menopause is defined as amenorrhea \>= 12 consecutive months. Note: women who have been amenorrheic for 12 or more months are still considered to be of childbearing potential if the amenorrhea is possibly due to prior chemotherapy, antiestrogens, ovarian suppression or any other reversible reason * Pregnant women may not participate in this study because with cabozantinib, nivolumab, and ipilimumab have potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with cabozantinib, nivolumab, and ipilimumab, breastfeeding should be discontinued if the mother is treated with these agents * The patient has received no cytotoxic chemotherapy (including investigational cytotoxic chemotherapy) or biologic agents (e.g., cytokines or antibodies) within 2 weeks before the first dose of study treatment * The patient has received no radiation therapy: * To the lungs and mediastinum or abdomen within 4 weeks before the first dose of study treatment, or has ongoing complications, or is healing from prior radiation therapy * To brain metastasis within 3 weeks for whole-brain radiotherapy (WBXRT), and 2 weeks for stereotactic body radiation therapy (SBRT) before the first dose of study treatment * To the abdomen within 4 weeks before the first dose of study treatment, or has ongoing complications, or is healing from prior radiation therapy * To any other site(s) within 2 weeks before the first dose of study treatment * The patient has received no radionuclide treatment within 6 weeks of the first dose of study treatment * The patient has received no prior treatment with a small molecule kinase inhibitor within 14 days or five half-lives of the compound or active metabolites, whichever is longer, before the first dose of study treatment * The patient has received no prior treatment with hormonal therapy within 14 days or five half-lives of the compound or active metabolites, whichever is longer, before the first dose of study treatment. Subjects receiving gonadotropin-releasing hormone (GnRH) agonists and antagonists are allowed to participate * The patient has not received any other type of investigational agent within 14 days before the first dose of study treatment * The patient must have recovered to baseline or Common Terminology Criteria for Adverse Events (CTCAE) =\< grade 1 from toxicity due to all prior therapies except alopecia, neuropathy and other non-clinically significant adverse events (AEs) defined as lab elevation with no associated symptoms or sequelae * The patient may not have active brain metastases or epidural disease. Patients with brain metastases previously treated with whole brain radiation or radiosurgery who are asymptomatic and do not require steroid treatment for at least 2 weeks before starting study treatment are eligible. Neurosurgical resection of brain metastases or brain biopsy is permitted if completed at least 3 months before starting study treatment. Baseline brain imaging with contrast-enhanced CT or MRI scans for subjects with known brain metastases is required to confirm eligibility * No concomitant treatment with warfarin. Aspirin (up to 325 mg/day), thrombin or factor Xa inhibitors, low-dose warfarin (=\< 1 mg/day), prophylactic and therapeutic low molecular weight heparin (LMWH) are permitted * No chronic concomitant treatment with strong CYP3A4 inducers (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentine, phenobarbital, and St. John's wort) or strong CYP3A4 inhibitors * Because the lists of these agents are constantly changing, it is important to regularly consult medical reference texts such as the Physicians' Desk Reference may also provide this information. As part of the enrollment/informed consent procedures, the patient will be counseled on the risk of interactions with other agents, and what to do if new medications need to be prescribed or if the patient is considering a new over-the-counter medicine or herbal product * The patient has not experienced any of the following: * Clinically-significant gastrointestinal bleeding within 6 months before the first dose of study treatment * Hemoptysis of \>= 0.5 teaspoon (2.5 mL) of red blood per day within 1 months before the first dose of study treatment * Any other signs indicative of pulmonary hemorrhage within 3 months before the first dose of study treatment * The patient has no tumor invading any major blood vessels * The patient has no evidence of tumor invading the GI tract (esophagus, stomach, small or large bowel, rectum or anus), or any evidence of endotracheal or endobronchial tumor within 28 days before the first dose of cabozantinib. Patients with rectal tumor masses are not eligible * The patient has no uncontrolled, significant intercurrent or recent illness including, but not limited to, the following conditions: * Cardiovascular disorders including: * Congestive heart failure (CHF): New York Heart Association (NYHA) class III (moderate) or class IV (severe) at the time of screening. * Concurrent uncontrolled hypertension defined as sustained blood pressure (BP) \> 150 mm Hg systolic, or \> 90 mm Hg diastolic despite optimal antihypertensive treatment within 7 days of the first dose of study treatment * The subject has a corrected QT interval calculated by the Fridericia formula (QTcF) \> 500 ms within 28 days before randomization. Note: if initial QTcF is found to be \> 500 ms, two additional electrocardiograms (EKGs) separated by at least 3 minutes should be performed. If the average of these three consecutive results for QTcF is =\< 500 ms, the subject meets eligibility in this regard * Any history of congenital long QT syndrome * Any of the following within 6 months before registration of study treatment: * Unstable angina pectoris * Clinically-significant cardiac arrhythmias (patients with atrial fibrillation are eligible) * Stroke (including transient ischemic attack \[TIA\], or other ischemic event) * Myocardial infarction * Cardiomyopathy * No significant gastrointestinal disorders particularly those associated with a high risk of perforation or fistula formation including: * Any of the following that have not resolved within 28 days before the first dose of study treatment: * Active peptic ulcer disease * Acute diverticulitis, cholecystitis, symptomatic cholangitis or appendicitis, or malabsorption syndrome * None of the following within 2 years before the first dose of study treatment: * Abdominal fistula or genitourinary fistula * Gastrointestinal perforation * Bowel obstruction or gastric outlet obstruction * Intra-abdominal abscess. Note: Complete resolution of an intra-abdominal abscess must be confirmed prior to initiating treatment with cabozantinib even if the abscess occurred more than 2 years before the first dose of study treatment * Disorders associated with a high risk of fistula formation including percutaneous endoscopic gastrostomy (PEG) tube placement are not eligible * No other clinically significant disorders such as: * Severe active infection requiring IV systemic treatment within 14 days before the first dose of study treatment * Serious non-healing wound/ulcer/bone fracture within 28 days before the first dose of study treatment * History of organ or allogeneic stem cell transplant * Concurrent uncompensated hypothyroidism or thyroid dysfunction within 7 days before the first dose of study treatment (for asymptomatic patients with an elevated thyroid-stimulating hormone \[TSH\], thyroid replacement may be initiated if clinically indicated without delaying the start of study treatment) * No history of major surgery as follows: * Major surgery within 3 months of the first dose of cabozantinib; however, if there were no wound healing complications, patients with rapidly growing aggressive cancers, may start as soon as 6 weeks if wound has completely healed post-surgery * Minor surgery within 1 month of the first dose of cabozantinib if there were no wound healing complications or within 3 months of the first dose of cabozantinib if there were wound complications excluding core biopsies and mediport placement * Complete wound healing from prior surgery must be confirmed before the first dose of cabozantinib irrespective of the time from surgery * No history of severe hypersensitivity reaction to any monoclonal antibody * No evidence of active malignancy, requiring systemic treatment within 2 years of registration * No history of allergic reactions attributed to compounds of similar chemical or biologic composition to cabozantinib, nivolumab, ipilimumab or other agents used in study * No positive test for hepatitis B virus surface antigen (HBV sAg) or hepatitis C virus ribonucleic acid (HCV antibody) indicating acute or chronic infection. If HBV sAG is positive, subsequent ribonucleic acid (RNA) polymerase chain reaction (PCR) must be negative * No patients with active autoimmune disease or history of autoimmune disease that might recur, which may affect vital organ function or require immune suppressive treatment including systemic corticosteroids. These include, but are not limited to patients with a history of immune related neurologic disease, multiple sclerosis, autoimmune (demyelinating) neuropathy, Guillain-Barre syndrome, myasthenia gravis; systemic autoimmune disease such as systemic lupus erythematosus (SLE), connective tissue diseases, scleroderma, inflammatory bowel disease (IBD), Crohn's, ulcerative colitis, hepatitis; and patients with a history of toxic epidermal necrolysis (TEN), Stevens-Johnson syndrome, or phospholipid syndrome should be excluded because of the risk of recurrence or exacerbation of disease

Study locations (579)

University of Alabama at Birmingham Cancer Center

Birmingham, Alabama, 35233

Active Not Recruiting

Anchorage Associates in Radiation Medicine

Anchorage, Alaska, 98508

Suspended

Anchorage Radiation Therapy Center

Anchorage, Alaska, 99504

Suspended

Alaska Breast Care and Surgery LLC

Anchorage, Alaska, 99508

Suspended

Alaska Oncology and Hematology LLC

Anchorage, Alaska, 99508

Suspended

Alaska Women's Cancer Care

Anchorage, Alaska, 99508

Suspended

Anchorage Oncology Centre

Anchorage, Alaska, 99508

Suspended

Katmai Oncology Group

Anchorage, Alaska, 99508

Suspended

Providence Alaska Medical Center

Anchorage, Alaska, 99508

Suspended

Kingman Regional Medical Center

Kingman, Arizona, 86401

Suspended

Cancer Center at Saint Joseph's

Phoenix, Arizona, 85004

Active Not Recruiting

Mayo Clinic Hospital in Arizona

Phoenix, Arizona, 85054

Recruiting
Site Public Contact · Contact
855-776-0015
Lance C. Pagliaro · Principal Investigator

Mayo Clinic in Arizona

Scottsdale, Arizona, 85259

Recruiting
Site Public Contact · Contact
855-776-0015
Lance C. Pagliaro · Principal Investigator

University of Arizona Cancer Center-Orange Grove Campus

Tucson, Arizona, 85704

Active Not Recruiting

Banner University Medical Center - Tucson

Tucson, Arizona, 85719

Active Not Recruiting

University of Arizona Cancer Center-North Campus

Tucson, Arizona, 85719

Active Not Recruiting

Mercy Hospital Fort Smith

Fort Smith, Arkansas, 72903

Suspended

CHI Saint Vincent Cancer Center Hot Springs

Hot Springs, Arkansas, 71913

Suspended

Mission Hope Medical Oncology - Arroyo Grande

Arroyo Grande, California, 93420

Active Not Recruiting

PCR Oncology

Arroyo Grande, California, 93420

Suspended

Providence Saint Joseph Medical Center/Disney Family Cancer Center

Burbank, California, 91505

Suspended

Community Cancer Institute

Clovis, California, 93611

Active Not Recruiting

University Oncology Associates

Clovis, California, 93611

Active Not Recruiting

Epic Care-Dublin

Dublin, California, 94568

Active Not Recruiting

Bay Area Breast Surgeons Inc

Emeryville, California, 94608

Active Not Recruiting

Epic Care Partners in Cancer Care

Emeryville, California, 94608

Active Not Recruiting

Marin Cancer Care Inc

Greenbrae, California, 94904

Suspended

Keck Medicine of USC Koreatown

Los Angeles, California, 90020

Recruiting
Site Public Contact · Contact
213-388-0908
Anishka D'Souza · Principal Investigator

Los Angeles General Medical Center

Los Angeles, California, 90033

Suspended

USC / Norris Comprehensive Cancer Center

Los Angeles, California, 90033

Suspended

UCLA / Jonsson Comprehensive Cancer Center

Los Angeles, California, 90095

Completed

Contra Costa Regional Medical Center

Martinez, California, 94553-3156

Active Not Recruiting

USC Norris Oncology/Hematology-Newport Beach

Newport Beach, California, 92663

Suspended

Alta Bates Summit Medical Center - Summit Campus

Oakland, California, 94609

Suspended

Bay Area Tumor Institute

Oakland, California, 94609

Active Not Recruiting

Pacific Central Coast Health Center-San Luis Obispo

San Luis Obispo, California, 93401

Active Not Recruiting

Mission Hope Medical Oncology - Santa Maria

Santa Maria, California, 93444

Active Not Recruiting

Epic Care Cyberknife Center

Walnut Creek, California, 94597

Active Not Recruiting

Penrose-Saint Francis Healthcare

Colorado Springs, Colorado, 80907

Active Not Recruiting

Rocky Mountain Cancer Centers-Penrose

Colorado Springs, Colorado, 80907

Active Not Recruiting

AdventHealth Porter

Denver, Colorado, 80210

Suspended

CommonSpirit Cancer Center Mercy

Durango, Colorado, 81301

Active Not Recruiting

Mercy Medical Center

Durango, Colorado, 81301

Active Not Recruiting

CommonSpirit Saint Anthony Hospital Cancer Center

Lakewood, Colorado, 80228

Active Not Recruiting

AdventHealth Littleton

Littleton, Colorado, 80122

Suspended

Longmont United Hospital

Longmont, Colorado, 80501

Active Not Recruiting

Rocky Mountain Cancer Centers-Longmont

Longmont, Colorado, 80501

Active Not Recruiting

AdventHealth Parker

Parker, Colorado, 80138

Suspended

Saint Mary Corwin Medical Center

Pueblo, Colorado, 81004

Active Not Recruiting

MedStar Georgetown University Hospital

Washington D.C., District of Columbia, 20007

Recruiting
Site Public Contact · Contact
202-444-2223
Nancy A. Dawson · Principal Investigator

Mount Sinai Comprehensive Cancer Center at Aventura

Aventura, Florida, 33180

Active Not Recruiting

Holy Cross Hospital

Fort Lauderdale, Florida, 33308

Recruiting
Site Public Contact · Contact
eileen.georgi@holy-cross.com
Tareq Al baghdadi · Principal Investigator

Mount Sinai Medical Center

Miami Beach, Florida, 33140

Active Not Recruiting

Orlando Health Cancer Institute

Orlando, Florida, 32806

Recruiting
Site Public Contact · Contact
321-841-7246CancerClinicalTrials@orlandohealth.com
Hatem Hassanein · Principal Investigator

Emory University Hospital Midtown

Atlanta, Georgia, 30308

Recruiting
Site Public Contact · Contact
888-946-7447
Mehmet A. Bilen · Principal Investigator

Emory University Hospital/Winship Cancer Institute

Atlanta, Georgia, 30322

Recruiting
Site Public Contact · Contact
404-778-1868
Mehmet A. Bilen · Principal Investigator

Emory Saint Joseph's Hospital

Atlanta, Georgia, 30342

Suspended

Emory Johns Creek Hospital

Johns Creek, Georgia, 30097

Suspended

Saint Alphonsus Cancer Care Center-Boise

Boise, Idaho, 83706

Recruiting
Site Public Contact · Contact
734-712-3671stephanie.couch@stjoeshealth.org
Tareq Al baghdadi · Principal Investigator

Saint Luke's Cancer Institute - Boise

Boise, Idaho, 83712

Suspended

Saint Alphonsus Cancer Care Center-Caldwell

Caldwell, Idaho, 83605

Recruiting
Site Public Contact · Contact
734-712-3671stephanie.couch@stjoeshealth.org
Tareq Al baghdadi · Principal Investigator

Kootenai Health - Coeur d'Alene

Coeur d'Alene, Idaho, 83814

Recruiting
Site Public Contact · Contact
406-969-6060mccinfo@mtcancer.org
John M. Schallenkamp · Principal Investigator

Walter Knox Memorial Hospital

Emmett, Idaho, 83617

Suspended

Saint Luke's Cancer Institute - Fruitland

Fruitland, Idaho, 83619

Suspended

Idaho Urologic Institute-Meridian

Meridian, Idaho, 83642

Suspended

Saint Luke's Cancer Institute - Meridian

Meridian, Idaho, 83642

Suspended

Saint Alphonsus Cancer Care Center-Nampa

Nampa, Idaho, 83687

Recruiting
Site Public Contact · Contact
406-969-6060mccinfo@mtcancer.org
Tareq Al baghdadi · Principal Investigator

Saint Luke's Cancer Institute - Nampa

Nampa, Idaho, 83687

Suspended

Kootenai Clinic Cancer Services - Post Falls

Post Falls, Idaho, 83854

Recruiting
Site Public Contact · Contact
406-969-6060mccinfo@mtcancer.org
John M. Schallenkamp · Principal Investigator

Kootenai Clinic Cancer Services - Sandpoint

Sandpoint, Idaho, 83864

Recruiting
Site Public Contact · Contact
406-969-6060mccinfo@mtcancer.org
John M. Schallenkamp · Principal Investigator

Saint Luke's Cancer Institute - Twin Falls

Twin Falls, Idaho, 83301

Suspended

OSF Saint Anthony's Health Center

Alton, Illinois, 62002

Suspended

Rush-Copley Medical Center

Aurora, Illinois, 60504

Suspended

Illinois CancerCare-Bloomington

Bloomington, Illinois, 61704

Suspended

Loyola Center for Health at Burr Ridge

Burr Ridge, Illinois, 60527

Suspended

Illinois CancerCare-Canton

Canton, Illinois, 61520

Suspended

Memorial Hospital of Carbondale

Carbondale, Illinois, 62902

Suspended

SIH Cancer Institute

Carterville, Illinois, 62918

Suspended

Illinois CancerCare-Carthage

Carthage, Illinois, 62321

Suspended

Northwestern University

Chicago, Illinois, 60611

Active Not Recruiting

Rush MD Anderson Cancer Center

Chicago, Illinois, 60612

Recruiting
Site Public Contact · Contact
312-226-2371Cancer_Studies@rush.edu
Thomas C. Westbrook · Principal Investigator

University of Illinois

Chicago, Illinois, 60612

Active Not Recruiting

University of Chicago Comprehensive Cancer Center

Chicago, Illinois, 60637

Recruiting
Site Public Contact · Contact
773-702-8222cancerclinicaltrials@bsd.uchicago.edu
Randy F. Sweis · Principal Investigator

Carle at The Riverfront

Danville, Illinois, 61832

Suspended

Cancer Care Specialists of Illinois - Decatur

Decatur, Illinois, 62526

Recruiting
Site Public Contact · Contact
217-876-4762morganthaler.jodi@mhsil.com
Bryan A. Faller · Principal Investigator

Decatur Memorial Hospital

Decatur, Illinois, 62526

Suspended

Illinois CancerCare-Dixon

Dixon, Illinois, 61021

Suspended

Carle Physician Group-Effingham

Effingham, Illinois, 62401

Suspended

Crossroads Cancer Center

Effingham, Illinois, 62401

Recruiting
Site Public Contact · Contact
217-876-4762morganthaler.jodi@mhsil.com
Bryan A. Faller · Principal Investigator

Illinois CancerCare-Eureka

Eureka, Illinois, 61530

Suspended

Illinois CancerCare-Galesburg

Galesburg, Illinois, 61401

Suspended

Western Illinois Cancer Treatment Center

Galesburg, Illinois, 61401

Suspended

Loyola Medicine Homer Glen

Homer Glen, Illinois, 60491

Suspended

Illinois CancerCare-Kewanee Clinic

Kewanee, Illinois, 61443

Suspended

Northwestern Medicine Lake Forest Hospital

Lake Forest, Illinois, 60045

Active Not Recruiting

Illinois CancerCare-Macomb

Macomb, Illinois, 61455

Suspended

Carle Physician Group-Mattoon/Charleston

Mattoon, Illinois, 61938

Suspended

Loyola University Medical Center

Maywood, Illinois, 60153

Recruiting
Site Public Contact · Contact
708-226-4357
Joseph I. Clark · Principal Investigator

Marjorie Weinberg Cancer Center at Loyola-Gottlieb

Melrose Park, Illinois, 60160

Suspended

SSM Health Good Samaritan

Mount Vernon, Illinois, 62864

Suspended

UC Comprehensive Cancer Center at Silver Cross

New Lenox, Illinois, 60451

Suspended

Cancer Care Center of O'Fallon

O'Fallon, Illinois, 62269

Suspended

Rush MD Anderson Cancer Center at Rush Oak Park

Oak Park, Illinois, 60304

Suspended

University of Chicago Medicine-Orland Park

Orland Park, Illinois, 60462

Suspended

Illinois CancerCare-Ottawa Clinic

Ottawa, Illinois, 61350

Suspended

Illinois CancerCare-Pekin

Pekin, Illinois, 61554

Suspended

Illinois CancerCare-Peoria

Peoria, Illinois, 61615

Suspended

Methodist Medical Center of Illinois

Peoria, Illinois, 61636

Suspended

Illinois CancerCare-Peru

Peru, Illinois, 61354

Suspended

Valley Radiation Oncology

Peru, Illinois, 61354

Suspended

Illinois CancerCare-Princeton

Princeton, Illinois, 61356

Suspended

Memorial Hospital East

Shiloh, Illinois, 62269

Recruiting
Site Public Contact · Contact
314-747-9912dschwab@wustl.edu
Melissa A. Reimers · Principal Investigator

Southern Illinois University School of Medicine

Springfield, Illinois, 62702

Recruiting
Site Public Contact · Contact
217-545-7929
Bryan A. Faller · Principal Investigator

Springfield Clinic

Springfield, Illinois, 62702

Recruiting
Site Public Contact · Contact
800-444-7541
Bryan A. Faller · Principal Investigator

Springfield Memorial Hospital

Springfield, Illinois, 62781

Recruiting
Site Public Contact · Contact
217-528-7541pallante.beth@mhsil.com
Bryan A. Faller · Principal Investigator

Southwest Illinois Health Services LLP

Swansea, Illinois, 62226

Suspended

Carle Cancer Center

Urbana, Illinois, 61801

Suspended

The Carle Foundation Hospital

Urbana, Illinois, 61801

Suspended

Illinois CancerCare - Washington

Washington, Illinois, 61571

Suspended

Rush-Copley Healthcare Center

Yorkville, Illinois, 60560

Suspended

Reid Health

Richmond, Indiana, 47374

Suspended

Mary Greeley Medical Center

Ames, Iowa, 50010

Recruiting
Site Public Contact · Contact
515-956-4132
Joseph J. Merchant · Principal Investigator

McFarland Clinic - Ames

Ames, Iowa, 50010

Recruiting
Site Public Contact · Contact
515-239-4734ksoder@mcfarlandclinic.com
Joseph J. Merchant · Principal Investigator

UI Health Care Mission Cancer and Blood - Ankeny Clinic

Ankeny, Iowa, 50023

Recruiting
Site Public Contact · Contact
515-241-3305
Seema Harichand-Herdt · Principal Investigator

University of Iowa Healthcare Cancer Services Quad Cities

Bettendorf, Iowa, 52722

Recruiting
Site Public Contact · Contact
563-355-7733katherine-daprile@uiowa.edu
Fernando Maciel Barbosa · Principal Investigator

McFarland Clinic - Boone

Boone, Iowa, 50036

Suspended

Mercy Cancer Center-West Lakes

Clive, Iowa, 50325

Suspended

UI Health Care Mission Cancer and Blood - West Des Moines Clinic

Clive, Iowa, 50325

Recruiting
Site Public Contact · Contact
515-241-3305
Seema Harichand-Herdt · Principal Investigator

Alegent Health Mercy Hospital

Council Bluffs, Iowa, 51503

Active Not Recruiting

Greater Regional Medical Center

Creston, Iowa, 50801

Suspended

Iowa Methodist Medical Center

Des Moines, Iowa, 50309

Recruiting
Site Public Contact · Contact
515-241-6727
Seema Harichand-Herdt · Principal Investigator

UI Health Care Mission Cancer and Blood - Des Moines Clinic

Des Moines, Iowa, 50309

Recruiting
Site Public Contact · Contact
515-241-3305
Seema Harichand-Herdt · Principal Investigator

Mercy Medical Center - Des Moines

Des Moines, Iowa, 50314

Recruiting
Site Public Contact · Contact
515-241-3305
Richard L. Deming · Principal Investigator

UI Health Care Mission Cancer and Blood - Laurel Clinic

Des Moines, Iowa, 50314

Recruiting
Site Public Contact · Contact
515-241-3305
Seema Harichand-Herdt · Principal Investigator

McFarland Clinic - Trinity Cancer Center

Fort Dodge, Iowa, 50501

Recruiting
Site Public Contact · Contact
515-956-4132
Joseph J. Merchant · Principal Investigator

University of Iowa/Holden Comprehensive Cancer Center

Iowa City, Iowa, 52242

Recruiting
Site Public Contact · Contact
800-237-1225
Fernando Maciel Barbosa · Principal Investigator

McFarland Clinic - Jefferson

Jefferson, Iowa, 50129

Suspended

McFarland Clinic - Marshalltown

Marshalltown, Iowa, 50158

Recruiting
Site Public Contact · Contact
515-956-4132
Joseph J. Merchant · Principal Investigator

UI Health Care Mission Cancer and Blood - Waukee Clinic

Waukee, Iowa, 50263

Recruiting
Site Public Contact · Contact
515-241-3305
Seema Harichand-Herdt · Principal Investigator

Mercy Medical Center-West Lakes

West Des Moines, Iowa, 50266

Suspended

Cancer Center of Kansas - Chanute

Chanute, Kansas, 66720

Active Not Recruiting

Cancer Center of Kansas - Dodge City

Dodge City, Kansas, 67801

Active Not Recruiting

Cancer Center of Kansas - El Dorado

El Dorado, Kansas, 67042

Active Not Recruiting

University of Kansas Clinical Research Center

Fairway, Kansas, 66205

Suspended

Central Care Cancer Center - Garden City

Garden City, Kansas, 67846

Suspended

Central Care Cancer Center - Great Bend

Great Bend, Kansas, 67530

Suspended

HaysMed

Hays, Kansas, 67601

Recruiting
Site Public Contact · Contact
785-623-5774
Elizabeth M. Wulff · Principal Investigator

Cancer Center of Kansas-Independence

Independence, Kansas, 67301

Active Not Recruiting

Cancer Center of Kansas-Kingman

Kingman, Kansas, 67068

Active Not Recruiting

Lawrence Memorial Hospital

Lawrence, Kansas, 66044

Recruiting
Site Public Contact · Contact
785-505-2800Stephanie.Norris@LMH.ORG
Elizabeth M. Wulff · Principal Investigator

Cancer Center of Kansas-Liberal

Liberal, Kansas, 67905

Active Not Recruiting

Cancer Center of Kansas-Manhattan

Manhattan, Kansas, 66502

Active Not Recruiting

Cancer Center of Kansas - McPherson

McPherson, Kansas, 67460

Active Not Recruiting

Cancer Center of Kansas - Newton

Newton, Kansas, 67114

Active Not Recruiting

The University of Kansas Cancer Center - Olathe

Olathe, Kansas, 66061

Recruiting
Site Public Contact · Contact
913-588-1569OlatheCCResearch@kumc.edu
Elizabeth M. Wulff · Principal Investigator

Cancer Center of Kansas - Parsons

Parsons, Kansas, 67357

Active Not Recruiting

Freeman Physician Group of Pittsburg

Pittsburg, Kansas, 66762

Recruiting
Site Public Contact · Contact
BNMathew@freemanhealth.com
Elizabeth M. Wulff · Principal Investigator

Mercy Hospital Pittsburg

Pittsburg, Kansas, 66762

Suspended

Cancer Center of Kansas - Pratt

Pratt, Kansas, 67124

Active Not Recruiting

Cancer Center of Kansas - Salina

Salina, Kansas, 67401

Active Not Recruiting

Salina Regional Health Center

Salina, Kansas, 67401

Recruiting
Site Public Contact · Contact
785-452-7038mleepers@srhc.com
Elizabeth M. Wulff · Principal Investigator

University of Kansas Health System Saint Francis Campus

Topeka, Kansas, 66606

Recruiting
Site Public Contact · Contact
785-295-8000
Elizabeth M. Wulff · Principal Investigator

Cancer Center of Kansas - Wellington

Wellington, Kansas, 67152

Active Not Recruiting

University of Kansas Hospital-Westwood Cancer Center

Westwood, Kansas, 66205

Recruiting
Site Public Contact · Contact
913-588-3671KUCC_Navigation@kumc.edu
Elizabeth M. Wulff · Principal Investigator

Cancer Center of Kansas-Wichita Medical Arts Tower

Wichita, Kansas, 67208

Active Not Recruiting

Ascension Via Christi Hospitals Wichita

Wichita, Kansas, 67214

Active Not Recruiting

Cancer Center of Kansas - Wichita

Wichita, Kansas, 67214

Active Not Recruiting

Cancer Center of Kansas - Winfield

Winfield, Kansas, 67156

Active Not Recruiting

Flaget Memorial Hospital

Bardstown, Kentucky, 40004

Active Not Recruiting

Commonwealth Cancer Center-Corbin

Corbin, Kentucky, 40701

Active Not Recruiting

Saint Joseph Radiation Oncology Resource Center

Lexington, Kentucky, 40504

Active Not Recruiting

Saint Joseph Hospital East

Lexington, Kentucky, 40509

Active Not Recruiting

University of Kentucky/Markey Cancer Center

Lexington, Kentucky, 40536

Suspended

Saint Joseph London

London, Kentucky, 40741

Active Not Recruiting

Jewish Hospital

Louisville, Kentucky, 40202

Suspended

Saints Mary and Elizabeth Hospital

Louisville, Kentucky, 40215

Suspended

UofL Health Medical Center Northeast

Louisville, Kentucky, 40245

Suspended

Jewish Hospital Medical Center South

Shepherdsville, Kentucky, 40165

Suspended

Hematology/Oncology Clinic PLLC

Baton Rouge, Louisiana, 70809

Suspended

Louisiana Hematology Oncology Associates LLC

Baton Rouge, Louisiana, 70809

Recruiting
Site Public Contact · Contact
225-215-1353clinicalresearch@marybird.com
Victor T. Lin · Principal Investigator

Ochsner High Grove

Baton Rouge, Louisiana, 70836

Active Not Recruiting

Ochsner Medical Center Kenner

Kenner, Louisiana, 70065

Active Not Recruiting

Mary Bird Perkins Cancer Center - Metairie

Metairie, Louisiana, 70002

Recruiting
Site Public Contact · Contact
504-584-6990
Victor T. Lin · Principal Investigator

East Jefferson General Hospital

Metairie, Louisiana, 70006

Suspended

LSU Healthcare Network / Metairie Multi-Specialty Clinic

Metairie, Louisiana, 70006

Active Not Recruiting

Louisiana State University Health Science Center

New Orleans, Louisiana, 70112

Active Not Recruiting

Tulane University School of Medicine

New Orleans, Louisiana, 70112

Suspended

Ochsner Medical Center Jefferson

New Orleans, Louisiana, 70121

Active Not Recruiting

Greater Baltimore Medical Center

Baltimore, Maryland, 21204

Suspended

National Institutes of Health Clinical Center

Bethesda, Maryland, 20892

Recruiting
Site Public Contact · Contact
800-411-1222
Andrea B. Apolo · Principal Investigator

FMH James M Stockman Cancer Institute

Frederick, Maryland, 21702

Recruiting
Site Public Contact · Contact
301-668-7043
Patrick J. Mansky · Principal Investigator

Lahey Hospital and Medical Center

Burlington, Massachusetts, 01805

Recruiting
Site Public Contact · Contact
781-744-3421lhmc-cancer-clinical-trials@lahey.org
Brendan Connell · Principal Investigator

Lahey Clinic Peabody

Peabody, Massachusetts, 01960

Recruiting
Site Public Contact · Contact
781-744-3421lhmc-cancer-clinical-trials@lahey.org
Brendan Connell · Principal Investigator

Mercy Medical Center

Springfield, Massachusetts, 01104

Suspended

Beth Israel Deaconess Medical Center/Winchester Center for Cancer Care

Winchester, Massachusetts, 01890

Active Not Recruiting

Trinity Health Saint Joseph Mercy Hospital Ann Arbor

Ann Arbor, Michigan, 48106

Recruiting
Site Public Contact · Contact
734-712-7251MCRCwebsitecontactform@stjoeshealth.org
Tareq Al baghdadi · Principal Investigator

Trinity Health IHA Medical Group Hematology Oncology - Brighton

Brighton, Michigan, 48114

Recruiting
Site Public Contact · Contact
734-712-7251MCRCwebsitecontactform@stjoeshealth.org
Tareq Al baghdadi · Principal Investigator

Trinity Health Medical Center - Brighton

Brighton, Michigan, 48114

Recruiting
Site Public Contact · Contact
734-712-7251MCRCwebsitecontactform@stjoeshealth.org
Tareq Al baghdadi · Principal Investigator

Henry Ford Cancer Institute-Downriver

Brownstown, Michigan, 48183

Recruiting
Site Public Contact · Contact
313-916-3721CTOResearch@hfhs.org
Haythem Y. Ali · Principal Investigator

Trinity Health IHA Medical Group Hematology Oncology - Canton

Canton, Michigan, 48188

Recruiting
Site Public Contact · Contact
734-712-7251MCRCwebsitecontactform@stjoeshealth.org
Tareq Al baghdadi · Principal Investigator

Trinity Health Medical Center - Canton

Canton, Michigan, 48188

Recruiting
Site Public Contact · Contact
734-712-7251MCRCwebsitecontactform@stjoeshealth.org
Tareq Al baghdadi · Principal Investigator

Caro Cancer Center

Caro, Michigan, 48723

Suspended

Chelsea Hospital

Chelsea, Michigan, 48118

Recruiting
Site Public Contact · Contact
734-712-7251MCRCwebsitecontactform@stjoeshealth.org
Tareq Al baghdadi · Principal Investigator

Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital

Chelsea, Michigan, 48118

Recruiting
Site Public Contact · Contact
734-712-7251MCRCwebsitecontactform@stjoeshealth.org
Tareq Al baghdadi · Principal Investigator

Hematology Oncology Consultants-Clarkston

Clarkston, Michigan, 48346

Recruiting
Site Public Contact · Contact
734-712-7251MCRCwebsitecontactform@stjoeshealth.org
Tareq Al baghdadi · Principal Investigator

Newland Medical Associates-Clarkston

Clarkston, Michigan, 48346

Suspended

Henry Ford Macomb Hospital-Clinton Township

Clinton Township, Michigan, 48038

Recruiting
Site Public Contact · Contact
313-916-3721CTOResearch@hfhs.org
Haythem Y. Ali · Principal Investigator

Henry Ford Medical Center-Fairlane

Dearborn, Michigan, 48126

Recruiting
Site Public Contact · Contact
313-916-3721CTOResearch@hfhs.org
Haythem Y. Ali · Principal Investigator

Henry Ford Hospital

Detroit, Michigan, 48202

Recruiting
Site Public Contact · Contact
313-916-3721CTOResearch@hfhs.org
Haythem Y. Ali · Principal Investigator

Henry Ford Health Saint John Hospital

Detroit, Michigan, 48236

Recruiting
Site Public Contact · Contact
313-343-3166Kkeenan1@hfhs.org
Tareq Al baghdadi · Principal Investigator

Henry Ford River District Hospital

East China Township, Michigan, 48054

Recruiting
Site Public Contact · Contact
313-343-3166kforman1@hfhs.org
Tareq Al baghdadi · Principal Investigator

Cancer Hematology Centers - Flint

Flint, Michigan, 48503

Recruiting
Site Public Contact · Contact
810-762-8038wstrong@ghci.org
Tareq Al baghdadi · Principal Investigator

Genesee Hematology Oncology PC

Flint, Michigan, 48503

Suspended

Genesys Hurley Cancer Institute

Flint, Michigan, 48503

Recruiting
Site Public Contact · Contact
810-762-8038wstrong@ghci.org
Tareq Al baghdadi · Principal Investigator

Hurley Medical Center

Flint, Michigan, 48503

Recruiting
Site Public Contact · Contact
810-762-8038wstrong@ghci.org
Tareq Al baghdadi · Principal Investigator

Henry Ford Saint John Hospital - Academic

Grosse Pointe Woods, Michigan, 48236

Recruiting
Site Public Contact · Contact
313-343-3166kforman1@hfhs.org
Tareq Al baghdadi · Principal Investigator

Henry Ford Saint John Hospital - Breast

Grosse Pointe Woods, Michigan, 48236

Suspended

Henry Ford Saint John Hospital - Van Elslander

Grosse Pointe Woods, Michigan, 48236

Recruiting
Site Public Contact · Contact
313-343-3166kforman1@hfhs.org
Tareq Al baghdadi · Principal Investigator

Allegiance Health

Jackson, Michigan, 49201

Recruiting
Site Public Contact · Contact
313-916-3721CTOResearch@hfhs.org
Haythem Y. Ali · Principal Investigator

University of Michigan Health - Sparrow Lansing

Lansing, Michigan, 48912

Recruiting
Site Public Contact · Contact
517-364-3712harsha.trivedi@umhsparrow.org
Tareq Al baghdadi · Principal Investigator

Hope Cancer Clinic

Livonia, Michigan, 48154

Suspended

Trinity Health Saint Mary Mercy Livonia Hospital

Livonia, Michigan, 48154

Recruiting
Site Public Contact · Contact
734-712-7251MCRCwebsitecontactform@stjoeshealth.org
Tareq Al baghdadi · Principal Investigator

Henry Ford Saint John Hospital - Macomb Medical

Macomb, Michigan, 48044

Recruiting
Site Public Contact · Contact
313-343-3166kforman1@hfhs.org
Tareq Al baghdadi · Principal Investigator

Henry Ford Warren Hospital - Breast Macomb

Macomb, Michigan, 48044

Suspended

Saint Mary's Oncology/Hematology Associates of Marlette

Marlette, Michigan, 48453

Suspended

Henry Ford Medical Center-Columbus

Novi, Michigan, 48377

Recruiting
Site Public Contact · Contact
313-916-3721CTOResearch@hfhs.org
Haythem Y. Ali · Principal Investigator

Hope Cancer Center

Pontiac, Michigan, 48341

Suspended

Michigan Healthcare Professionals Pontiac

Pontiac, Michigan, 48341

Recruiting
Site Public Contact · Contact
248-858-6215Emily.Crofts@trinity-health.org
Tareq Al baghdadi · Principal Investigator

Newland Medical Associates-Pontiac

Pontiac, Michigan, 48341

Recruiting
Site Public Contact · Contact
734-712-7251MCRCwebsitecontactform@stjoeshealth.org
Tareq Al baghdadi · Principal Investigator

Trinity Health Saint Joseph Mercy Oakland Hospital

Pontiac, Michigan, 48341

Recruiting
Site Public Contact · Contact
734-712-7251MCRCwebsitecontactform@stjoeshealth.org
Tareq Al baghdadi · Principal Investigator

Huron Medical Center PC

Port Huron, Michigan, 48060

Suspended

Lake Huron Medical Center

Port Huron, Michigan, 48060

Suspended

Henry Ford Rochester Hospital

Rochester Hills, Michigan, 48309

Suspended

MyMichigan Medical Center Saginaw

Saginaw, Michigan, 48601

Recruiting
Site Public Contact · Contact
734-712-7251MCRCwebsitecontactform@stjoeshealth.org
Tareq Al baghdadi · Principal Investigator

Oncology Hematology Associates of Saginaw Valley PC

Saginaw, Michigan, 48604

Suspended

Henry Ford Macomb Health Center - Shelby Township

Shelby, Michigan, 48315

Suspended

Bhadresh Nayak MD PC-Sterling Heights

Sterling Heights, Michigan, 48312

Suspended

MyMichigan Medical Center Tawas

Tawas City, Michigan, 48764

Recruiting
Site Public Contact · Contact
734-712-7251MCRCwebsitecontactform@stjoeshealth.org
Tareq Al baghdadi · Principal Investigator

Advanced Breast Care Center PLLC

Warren, Michigan, 48088

Suspended

Henry Ford Health Warren Hospital

Warren, Michigan, 48093

Recruiting
Site Public Contact · Contact
313-343-3166kforman1@hfhs.org
Tareq Al baghdadi · Principal Investigator

Henry Ford Madison Heights Hospital - Breast

Warren, Michigan, 48093

Suspended

Henry Ford Warren Hospital - GLCMS

Warren, Michigan, 48093

Recruiting
Site Public Contact · Contact
313-343-3166kforman1@hfhs.org
Tareq Al baghdadi · Principal Investigator

Macomb Hematology Oncology PC

Warren, Michigan, 48093

Suspended

Henry Ford West Bloomfield Hospital

West Bloomfield, Michigan, 48322

Recruiting
Site Public Contact · Contact
313-916-3721CTOResearch@hfhs.org
Haythem Y. Ali · Principal Investigator

Saint Mary's Oncology/Hematology Associates of West Branch

West Branch, Michigan, 48661

Suspended

Henry Ford Wyandotte Hospital

Wyandotte, Michigan, 48192

Recruiting
Site Public Contact · Contact
nhay@hfhs.org
Haythem Y. Ali · Principal Investigator

Huron Gastroenterology PC

Ypsilanti, Michigan, 48106

Recruiting
Site Public Contact · Contact
734-712-7251MCRCwebsitecontactform@stjoeshealth.org
Tareq Al baghdadi · Principal Investigator

Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus

Ypsilanti, Michigan, 48197

Recruiting
Site Public Contact · Contact
734-712-7251MCRCwebsitecontactform@stjoeshealth.org
Tareq Al baghdadi · Principal Investigator

Riverwood Healthcare Center

Aitkin, Minnesota, 56431

Suspended

Essentia Health Saint Joseph's Medical Center

Brainerd, Minnesota, 56401

Suspended

Fairview Ridges Hospital

Burnsville, Minnesota, 55337

Suspended

Minnesota Oncology - Burnsville

Burnsville, Minnesota, 55337

Suspended

Cambridge Medical Center

Cambridge, Minnesota, 55008

Suspended

Mercy Hospital

Coon Rapids, Minnesota, 55433

Suspended

Essentia Health - Deer River Clinic

Deer River, Minnesota, 56636

Recruiting
Site Public Contact · Contact
218-786-3308CancerTrials@EssentiaHealth.org
Bret E. Friday · Principal Investigator

Essentia Health Saint Mary's - Detroit Lakes Clinic

Detroit Lakes, Minnesota, 56501

Suspended

Essentia Health Cancer Center

Duluth, Minnesota, 55805

Recruiting
Site Public Contact · Contact
218-786-3308CancerTrials@EssentiaHealth.org
Bret E. Friday · Principal Investigator

Essentia Health Saint Mary's Medical Center

Duluth, Minnesota, 55805

Suspended

Miller-Dwan Hospital

Duluth, Minnesota, 55805

Suspended

Fairview Southdale Hospital

Edina, Minnesota, 55435

Recruiting
Site Public Contact · Contact
952-993-1517mmcorc@healthpartners.com
Daniel M. Anderson · Principal Investigator

Lake Region Healthcare Corporation-Cancer Care

Fergus Falls, Minnesota, 56537

Suspended

Essentia Health - Fosston

Fosston, Minnesota, 56542

Suspended

Unity Hospital

Fridley, Minnesota, 55432

Active Not Recruiting

Essentia Health Hibbing Clinic

Hibbing, Minnesota, 55746

Recruiting
Site Public Contact · Contact
218-786-3308
Bret E. Friday · Principal Investigator

Fairview Clinics and Surgery Center Maple Grove

Maple Grove, Minnesota, 55369

Suspended

Minnesota Oncology Hematology PA-Maplewood

Maplewood, Minnesota, 55109

Suspended

Saint John's Hospital - Healtheast

Maplewood, Minnesota, 55109

Suspended

Abbott-Northwestern Hospital

Minneapolis, Minnesota, 55407

Suspended

Hennepin County Medical Center

Minneapolis, Minnesota, 55415

Recruiting
Site Public Contact · Contact
952-993-1517mmcorc@healthpartners.com
Daniel M. Anderson · Principal Investigator

Health Partners Inc

Minneapolis, Minnesota, 55454

Suspended

Monticello Cancer Center

Monticello, Minnesota, 55362

Suspended

New Ulm Medical Center

New Ulm, Minnesota, 56073

Suspended

Essentia Health - Park Rapids

Park Rapids, Minnesota, 56470

Suspended

Fairview Northland Medical Center

Princeton, Minnesota, 55371

Suspended

North Memorial Medical Health Center

Robbinsdale, Minnesota, 55422

Suspended

Mayo Clinic in Rochester

Rochester, Minnesota, 55905

Recruiting
Site Public Contact · Contact
855-776-0015
Lance C. Pagliaro · Principal Investigator

Park Nicollet Clinic - Saint Louis Park

Saint Louis Park, Minnesota, 55416

Suspended

Regions Hospital

Saint Paul, Minnesota, 55101

Recruiting
Site Public Contact · Contact
952-993-1517mmcorc@healthpartners.com
Daniel M. Anderson · Principal Investigator

United Hospital

Saint Paul, Minnesota, 55102

Suspended

Essentia Health Sandstone

Sandstone, Minnesota, 55072

Recruiting
Site Public Contact · Contact
218-786-3308CancerTrials@EssentiaHealth.org
Bret E. Friday · Principal Investigator

Saint Francis Regional Medical Center

Shakopee, Minnesota, 55379

Suspended

Lakeview Hospital

Stillwater, Minnesota, 55082

Recruiting
Site Public Contact · Contact
952-993-1517mmcorc@healthpartners.com
Daniel M. Anderson · Principal Investigator

Essentia Health Virginia Clinic

Virginia, Minnesota, 55792

Recruiting
Site Public Contact · Contact
218-786-3308CancerTrials@EssentiaHealth.org
Bret E. Friday · Principal Investigator

Ridgeview Medical Center

Waconia, Minnesota, 55387

Recruiting
Site Public Contact · Contact
952-993-1517mmcorc@healthpartners.com
Daniel M. Anderson · Principal Investigator

Rice Memorial Hospital

Willmar, Minnesota, 56201

Suspended

Minnesota Oncology Hematology PA-Woodbury

Woodbury, Minnesota, 55125

Suspended

Fairview Lakes Medical Center

Wyoming, Minnesota, 55092

Suspended

University of Mississippi Medical Center

Jackson, Mississippi, 39216

Recruiting
Site Public Contact · Contact
601-815-6700
John C. Henegan · Principal Investigator

Mercy Oncology and Hematology - Clayton-Clarkson

Ballwin, Missouri, 63011

Suspended

Central Care Cancer Center - Bolivar

Bolivar, Missouri, 65613

Suspended

Parkland Health Center-Bonne Terre

Bonne Terre, Missouri, 63628

Suspended

Cox Cancer Center Branson

Branson, Missouri, 65616

Suspended

Mercy Cancer Center - Cape Girardeau

Cape Girardeau, Missouri, 63703

Suspended

Saint Francis Medical Center

Cape Girardeau, Missouri, 63703

Recruiting
Site Public Contact · Contact
573-334-2230sfmc@sfmc.net
Bryan A. Faller · Principal Investigator

Siteman Cancer Center at Saint Peters Hospital

City of Saint Peters, Missouri, 63376

Recruiting
Site Public Contact · Contact
800-600-3606info@siteman.wustl.edu
Melissa A. Reimers · Principal Investigator

Siteman Cancer Center at West County Hospital

Creve Coeur, Missouri, 63141

Recruiting
Site Public Contact · Contact
800-600-3606info@siteman.wustl.edu
Melissa A. Reimers · Principal Investigator

Parkland Health Center - Farmington

Farmington, Missouri, 63640

Recruiting
Site Public Contact · Contact
314-996-5569
Bryan A. Faller · Principal Investigator

MU Health Care Goldschmidt Cancer Center

Jefferson City, Missouri, 65109

Suspended

Freeman Health System

Joplin, Missouri, 64804

Suspended

Mercy Hospital Joplin

Joplin, Missouri, 64804

Suspended

University Health Truman Medical Center

Kansas City, Missouri, 64108

Recruiting
Site Public Contact · Contact
816-404-4375
Elizabeth M. Wulff · Principal Investigator

University of Kansas Cancer Center - Lee's Summit

Lee's Summit, Missouri, 64064

Recruiting
Site Public Contact · Contact
913-588-3671KUCC_Navigation@kumc.edu
Elizabeth M. Wulff · Principal Investigator

Mercy Clinic-Rolla-Cancer and Hematology

Rolla, Missouri, 65401

Suspended

Phelps Health Delbert Day Cancer Institute

Rolla, Missouri, 65401

Suspended

Heartland Regional Medical Center

Saint Joseph, Missouri, 64506

Suspended

Sainte Genevieve County Memorial Hospital

Sainte Genevieve, Missouri, 63670

Recruiting
Site Public Contact · Contact
314-996-5569
Bryan A. Faller · Principal Investigator

Mercy Hospital Springfield

Springfield, Missouri, 65804

Suspended

CoxHealth South Hospital

Springfield, Missouri, 65807

Suspended

Mercy Infusion Center - Chippewa

St Louis, Missouri, 63109

Suspended

Washington University School of Medicine

St Louis, Missouri, 63110

Recruiting
Site Public Contact · Contact
800-600-3606info@siteman.wustl.edu
Melissa A. Reimers · Principal Investigator

Mercy Hospital South

St Louis, Missouri, 63128

Recruiting
Site Public Contact · Contact
314-525-6042Danielle.Werle@mercy.net
Jay W. Carlson · Principal Investigator

Siteman Cancer Center-South County

St Louis, Missouri, 63129

Recruiting
Site Public Contact · Contact
800-600-3606info@siteman.wustl.edu
Melissa A. Reimers · Principal Investigator

Missouri Baptist Medical Center

St Louis, Missouri, 63131

Recruiting
Site Public Contact · Contact
314-996-5569
Bryan A. Faller · Principal Investigator

Siteman Cancer Center at Christian Hospital

St Louis, Missouri, 63136

Recruiting
Site Public Contact · Contact
800-600-3606info@siteman.wustl.edu
Melissa A. Reimers · Principal Investigator

Mercy Hospital Saint Louis

St Louis, Missouri, 63141

Recruiting
Site Public Contact · Contact
314-251-7066
Jay W. Carlson · Principal Investigator

Missouri Baptist Sullivan Hospital

Sullivan, Missouri, 63080

Recruiting
Site Public Contact · Contact
314-996-5569
Bryan A. Faller · Principal Investigator

BJC Outpatient Center at Sunset Hills

Sunset Hills, Missouri, 63127

Recruiting
Site Public Contact · Contact
314-996-5569
Bryan A. Faller · Principal Investigator

Mercy Hospital Washington

Washington, Missouri, 63090

Suspended

Community Hospital of Anaconda

Anaconda, Montana, 59711

Recruiting
Site Public Contact · Contact
406-969-6060mccinfo@mtcancer.org
John M. Schallenkamp · Principal Investigator

Billings Clinic Cancer Center

Billings, Montana, 59101

Recruiting
Site Public Contact · Contact
800-996-2663research@billingsclinic.org
John M. Schallenkamp · Principal Investigator

Bozeman Health Deaconess Hospital

Bozeman, Montana, 59715

Recruiting
Site Public Contact · Contact
406-969-6060mccinfo@mtcancer.org
John M. Schallenkamp · Principal Investigator

Benefis Sletten Cancer Institute

Great Falls, Montana, 59405

Recruiting
Site Public Contact · Contact
406-969-6060mccinfo@mtcancer.org
John M. Schallenkamp · Principal Investigator

Great Falls Clinic

Great Falls, Montana, 59405

Suspended

Saint Peter's Community Hospital

Helena, Montana, 59601

Suspended

Logan Health Medical Center

Kalispell, Montana, 59901

Recruiting
Site Public Contact · Contact
406-969-6060mccinfo@mtcancer.org
John M. Schallenkamp · Principal Investigator

Saint Patrick Hospital - Community Hospital

Missoula, Montana, 59802

Suspended

Community Medical Center

Missoula, Montana, 59804

Recruiting
Site Public Contact · Contact
406-969-6060mccinfo@mtcancer.org
John M. Schallenkamp · Principal Investigator

Nebraska Medicine-Bellevue

Bellevue, Nebraska, 68123

Recruiting
Site Public Contact · Contact
402-559-6941unmcrsa@unmc.edu
Benjamin A. Teply · Principal Investigator

Nebraska Cancer Specialists/Oncology Hematology West PC

Grand Island, Nebraska, 68803

Suspended

CHI Health Good Samaritan

Kearney, Nebraska, 68847

Active Not Recruiting

Saint Elizabeth Regional Medical Center

Lincoln, Nebraska, 68510

Active Not Recruiting

Nebraska Cancer Specialists/Oncology Hematology West PC - MECC

Omaha, Nebraska, 68114

Suspended

Nebraska Methodist Hospital

Omaha, Nebraska, 68114

Suspended

Oncology Associates PC

Omaha, Nebraska, 68114

Suspended

Nebraska Medicine-Village Pointe

Omaha, Nebraska, 68118

Recruiting
Site Public Contact · Contact
402-559-5600
Benjamin A. Teply · Principal Investigator

Alegent Health Immanuel Medical Center

Omaha, Nebraska, 68122

Active Not Recruiting

Alegent Health Bergan Mercy Medical Center

Omaha, Nebraska, 68124

Active Not Recruiting

Alegent Health Lakeside Hospital

Omaha, Nebraska, 68130

Active Not Recruiting

University of Nebraska Medical Center

Omaha, Nebraska, 68198

Recruiting
Site Public Contact · Contact
402-559-6941unmcrsa@unmc.edu
Benjamin A. Teply · Principal Investigator

Midlands Community Hospital

Papillion, Nebraska, 68046

Active Not Recruiting

Carson Tahoe Regional Medical Center

Carson City, Nevada, 89703

Suspended

Cancer and Blood Specialists-Henderson

Henderson, Nevada, 89052

Suspended

Comprehensive Cancer Centers of Nevada - Henderson

Henderson, Nevada, 89052

Suspended

Comprehensive Cancer Centers of Nevada-Horizon Ridge

Henderson, Nevada, 89052

Suspended

Las Vegas Cancer Center-Henderson

Henderson, Nevada, 89052

Suspended

Comprehensive Cancer Centers of Nevada-Southeast Henderson

Henderson, Nevada, 89074

Suspended

Las Vegas Urology - Green Valley

Henderson, Nevada, 89074

Suspended

Las Vegas Urology - Pebble

Henderson, Nevada, 89074

Suspended

Oncology Las Vegas - Henderson

Henderson, Nevada, 89074

Suspended

Urology Specialists of Nevada - Green Valley

Henderson, Nevada, 89074

Suspended

Las Vegas Urology - Pecos

Las Vegas, Nevada, 89074

Suspended

Desert West Surgery

Las Vegas, Nevada, 89102

Suspended

OptumCare Cancer Care at Charleston

Las Vegas, Nevada, 89102

Recruiting
Site Public Contact · Contact
702-384-0013research@sncrf.org
John A. Ellerton · Principal Investigator

University Medical Center of Southern Nevada

Las Vegas, Nevada, 89102

Suspended

Hope Cancer Care of Nevada

Las Vegas, Nevada, 89103

Suspended

Cancer and Blood Specialists-Shadow

Las Vegas, Nevada, 89106

Suspended

Radiation Oncology Centers of Nevada Central

Las Vegas, Nevada, 89106

Suspended

Urology Specialists of Nevada - Central

Las Vegas, Nevada, 89106

Suspended

HealthCare Partners Medical Group Oncology/Hematology-Maryland Parkway

Las Vegas, Nevada, 89109

Suspended

Sunrise Hospital and Medical Center

Las Vegas, Nevada, 89109

Suspended

HealthCare Partners Medical Group Oncology/Hematology-San Martin

Las Vegas, Nevada, 89113

Suspended

Las Vegas Prostate Cancer Center

Las Vegas, Nevada, 89113

Suspended

Las Vegas Urology - Sunset

Las Vegas, Nevada, 89113

Suspended

Urology Specialists of Nevada - Southwest

Las Vegas, Nevada, 89113

Suspended

Radiation Oncology Centers of Nevada Southeast

Las Vegas, Nevada, 89119

Suspended

Ann M Wierman MD LTD

Las Vegas, Nevada, 89128

Suspended

Cancer and Blood Specialists-Tenaya

Las Vegas, Nevada, 89128

Suspended

Comprehensive Cancer Centers of Nevada - Northwest

Las Vegas, Nevada, 89128

Suspended

HealthCare Partners Medical Group Oncology/Hematology-Tenaya

Las Vegas, Nevada, 89128

Suspended

Las Vegas Urology - Cathedral Rock

Las Vegas, Nevada, 89128

Suspended

Las Vegas Urology - Smoke Ranch

Las Vegas, Nevada, 89128

Suspended

Oncology Las Vegas - Tenaya

Las Vegas, Nevada, 89128

Suspended

OptumCare Cancer Care at MountainView

Las Vegas, Nevada, 89128

Suspended

Urology Specialists of Nevada - Northwest

Las Vegas, Nevada, 89128

Suspended

Alliance for Childhood Diseases/Cure 4 the Kids Foundation

Las Vegas, Nevada, 89135

Suspended

Comprehensive Cancer Centers of Nevada - Town Center

Las Vegas, Nevada, 89144

Suspended

Comprehensive Cancer Centers of Nevada-Summerlin

Las Vegas, Nevada, 89144

Suspended

Summerlin Hospital Medical Center

Las Vegas, Nevada, 89144

Suspended

Las Vegas Cancer Center-Medical Center

Las Vegas, Nevada, 89148-2405

Suspended

Comprehensive Cancer Centers of Nevada

Las Vegas, Nevada, 89148

Suspended

HealthCare Partners Medical Group Oncology/Hematology-Centennial Hills

Las Vegas, Nevada, 89149

Suspended

Comprehensive Cancer Centers of Nevada - Central Valley

Las Vegas, Nevada, 89169

Suspended

University Cancer Center

Las Vegas, Nevada, 89169

Suspended

OptumCare Cancer Care at Fort Apache

Las Vegas, Nevada, 89183

Recruiting
Site Public Contact · Contact
702-384-0013research@sncrf.org
John A. Ellerton · Principal Investigator

Hope Cancer Care of Nevada-Pahrump

Pahrump, Nevada, 89048

Suspended

Renown Regional Medical Center

Reno, Nevada, 89502

Suspended

Saint Mary's Regional Medical Center

Reno, Nevada, 89503

Suspended

Radiation Oncology Associates

Reno, Nevada, 89509

Suspended

Memorial Sloan Kettering Basking Ridge

Basking Ridge, New Jersey, 07920

Recruiting
Site Public Contact · Contact
212-639-7592
Samuel A. Funt · Principal Investigator

Memorial Sloan Kettering Monmouth

Middletown, New Jersey, 07748

Recruiting
Site Public Contact · Contact
212-639-7592
Samuel A. Funt · Principal Investigator

Memorial Sloan Kettering Bergen

Montvale, New Jersey, 07645

Recruiting
Site Public Contact · Contact
212-639-7592
Samuel A. Funt · Principal Investigator

New York-Presbyterian/Brooklyn Methodist Hospital

Brooklyn, New York, 11215

Active Not Recruiting

Maimonides Medical Center

Brooklyn, New York, 11219

Active Not Recruiting

Roswell Park Cancer Institute

Buffalo, New York, 14263

Active Not Recruiting

Memorial Sloan Kettering Commack

Commack, New York, 11725

Recruiting
Site Public Contact · Contact
212-639-7592
Samuel A. Funt · Principal Investigator

Memorial Sloan Kettering Westchester

Harrison, New York, 10604

Recruiting
Site Public Contact · Contact
212-639-7592
Samuel A. Funt · Principal Investigator

Northwell Health/Center for Advanced Medicine

Lake Success, New York, 11042

Active Not Recruiting

NYU Langone Hospital - Long Island

Mineola, New York, 11501

Recruiting
Site Public Contact · Contact
212-263-4432cancertrials@nyulangone.org
David R. Wise · Principal Investigator

Laura and Isaac Perlmutter Cancer Center at NYU Langone

New York, New York, 10016

Suspended

NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center

New York, New York, 10032

Recruiting
Site Public Contact · Contact
212-342-5162cancerclinicaltrials@cumc.columbia.edu
Mark N. Stein · Principal Investigator

Memorial Sloan Kettering Cancer Center

New York, New York, 10065

Recruiting
Site Public Contact · Contact
212-639-7592
Samuel A. Funt · Principal Investigator

NYP/Weill Cornell Medical Center

New York, New York, 10065

Recruiting
Site Public Contact · Contact
212-746-1848
Cora N. Sternberg · Principal Investigator

University of Rochester

Rochester, New York, 14642

Active Not Recruiting

State University of New York Upstate Medical University

Syracuse, New York, 13210

Active Not Recruiting

Memorial Sloan Kettering Nassau

Uniondale, New York, 11553

Recruiting
Site Public Contact · Contact
212-639-7592
Samuel A. Funt · Principal Investigator

UNC Lineberger Comprehensive Cancer Center

Chapel Hill, North Carolina, 27599

Recruiting
Site Public Contact · Contact
877-668-0683cancerclinicaltrials@med.unc.edu
Tracy L. Rose · Principal Investigator

Margaret R Pardee Memorial Hospital

Hendersonville, North Carolina, 28791

Recruiting
Site Public Contact · Contact
828-696-4716pardeecancerresearch@unchealth.unc.edu
John K. Hill · Principal Investigator

Essentia Health Cancer Center-South University Clinic

Fargo, North Dakota, 58103

Suspended

Essentia Health - Jamestown Clinic

Jamestown, North Dakota, 58401

Suspended

Indu and Raj Soin Medical Center

Beavercreek, Ohio, 45431

Suspended

Strecker Cancer Center-Belpre

Belpre, Ohio, 45714

Recruiting
Site Public Contact · Contact
614-488-2745Jeffh@columbusccop.org
Aruna C. Gowda · Principal Investigator

Saint Elizabeth Boardman Hospital

Boardman, Ohio, 44512

Suspended

Dayton Physicians LLC-Miami Valley South

Centerville, Ohio, 45459

Suspended

Miami Valley Hospital South

Centerville, Ohio, 45459

Active Not Recruiting

Adena Regional Medical Center

Chillicothe, Ohio, 45601

Recruiting
Site Public Contact · Contact
877-779-7585Jeffh@columbusccop.org
Aruna C. Gowda · Principal Investigator

University of Cincinnati Cancer Center-UC Medical Center

Cincinnati, Ohio, 45219

Active Not Recruiting

Good Samaritan Hospital - Cincinnati

Cincinnati, Ohio, 45220

Active Not Recruiting

Oncology Hematology Care Inc-Kenwood

Cincinnati, Ohio, 45236

Suspended

Bethesda North Hospital

Cincinnati, Ohio, 45242

Active Not Recruiting

TriHealth Cancer Institute-Westside

Cincinnati, Ohio, 45247

Active Not Recruiting

TriHealth Cancer Institute-Anderson

Cincinnati, Ohio, 45255

Active Not Recruiting

Ohio State University Comprehensive Cancer Center

Columbus, Ohio, 43210

Recruiting
Site Public Contact · Contact
800-293-5066Jamesline@osumc.edu
Amir Mortazavi · Principal Investigator

Mount Carmel East Hospital

Columbus, Ohio, 43213

Recruiting
Site Public Contact · Contact
614-488-2745Jeffh@columbusccop.org
Aruna C. Gowda · Principal Investigator

Columbus Oncology and Hematology Associates Inc

Columbus, Ohio, 43214

Recruiting
Site Public Contact · Contact
614-788-3860Jennifer.Sexton@ohiohealth.com
Shakir Sarwar · Principal Investigator

Riverside Methodist Hospital

Columbus, Ohio, 43214

Recruiting
Site Public Contact · Contact
614-788-3860Jennifer.Sexton@ohiohealth.com
Shakir Sarwar · Principal Investigator

Grant Medical Center

Columbus, Ohio, 43215

Recruiting
Site Public Contact · Contact
614-788-3860Jennifer.Sexton@ohiohealth.com
Shakir Sarwar · Principal Investigator

The Mark H Zangmeister Center

Columbus, Ohio, 43219

Recruiting
Site Public Contact · Contact
614-488-2745Jeffh@columbusccop.org
Aruna C. Gowda · Principal Investigator

Mount Carmel Health Center West

Columbus, Ohio, 43222

Recruiting
Site Public Contact · Contact
614-488-2745Jeffh@columbusccop.org
Aruna C. Gowda · Principal Investigator

Doctors Hospital

Columbus, Ohio, 43228

Recruiting
Site Public Contact · Contact
614-788-3860Jennifer.Sexton@ohiohealth.com
Shakir Sarwar · Principal Investigator

Good Samaritan Hospital - Dayton

Dayton, Ohio, 45406

Suspended

Miami Valley Hospital

Dayton, Ohio, 45409

Active Not Recruiting

Dayton Physician LLC - Englewood

Dayton, Ohio, 45415

Suspended

Miami Valley Hospital North

Dayton, Ohio, 45415

Active Not Recruiting

Delaware Health Center-Grady Cancer Center

Delaware, Ohio, 43015

Recruiting
Site Public Contact · Contact
614-788-3860Jennifer.Sexton@ohiohealth.com
Shakir Sarwar · Principal Investigator

Grady Memorial Hospital

Delaware, Ohio, 43015

Recruiting
Site Public Contact · Contact
614-788-3860Jennifer.Sexton@ohiohealth.com
Shakir Sarwar · Principal Investigator

Dublin Methodist Hospital

Dublin, Ohio, 43016

Suspended

Armes Family Cancer Center

Findlay, Ohio, 45840

Suspended

Blanchard Valley Hospital

Findlay, Ohio, 45840

Suspended

Orion Cancer Care

Findlay, Ohio, 45840

Suspended

Atrium Medical Center-Middletown Regional Hospital

Franklin, Ohio, 45005-1066

Suspended

Dayton Physicians LLC-Atrium

Franklin, Ohio, 45005

Suspended

Central Ohio Breast and Endocrine Surgery

Gahanna, Ohio, 43230

Suspended

Dayton Physicians LLC-Wayne

Greenville, Ohio, 45331

Suspended

Wayne Hospital

Greenville, Ohio, 45331

Suspended

Mount Carmel Grove City Hospital

Grove City, Ohio, 43123

Suspended

Greater Dayton Cancer Center

Kettering, Ohio, 45409

Suspended

First Dayton Cancer Care

Kettering, Ohio, 45420

Suspended

Kettering Medical Center

Kettering, Ohio, 45429

Recruiting
Site Public Contact · Contact
937-528-2900clinical.trials@daytonncorp.org
Howard M. Gross · Principal Investigator

Fairfield Medical Center

Lancaster, Ohio, 43130

Recruiting
Site Public Contact · Contact
614-488-2745Jeffh@columbusccop.org
Aruna C. Gowda · Principal Investigator

Saint Rita's Medical Center

Lima, Ohio, 45801

Suspended

OhioHealth Mansfield Hospital

Mansfield, Ohio, 44903

Recruiting
Site Public Contact · Contact
614-788-3860Jennifer.Sexton@ohiohealth.com
Shakir Sarwar · Principal Investigator

Marietta Memorial Hospital

Marietta, Ohio, 45750

Recruiting
Site Public Contact · Contact
614-488-2745Jeffh@columbusccop.org
Aruna C. Gowda · Principal Investigator

OhioHealth Marion General Hospital

Marion, Ohio, 43302

Recruiting
Site Public Contact · Contact
614-788-3860Jennifer.Sexton@ohiohealth.com
Shakir Sarwar · Principal Investigator

Memorial Hospital

Marysville, Ohio, 43040

Recruiting
Site Public Contact · Contact
614-488-2745Jeffh@columbusccop.org
Aruna C. Gowda · Principal Investigator

Knox Community Hospital

Mount Vernon, Ohio, 43050

Recruiting
Site Public Contact · Contact
614-488-2745Jeffh@columbusccop.org
Aruna C. Gowda · Principal Investigator

Licking Memorial Hospital

Newark, Ohio, 43055

Recruiting
Site Public Contact · Contact
614-488-2745Jeffh@columbusccop.org
Aruna C. Gowda · Principal Investigator

Newark Radiation Oncology

Newark, Ohio, 43055

Suspended

Mercy Health - Perrysburg Hospital

Perrysburg, Ohio, 43551

Suspended

Southern Ohio Medical Center

Portsmouth, Ohio, 45662

Recruiting
Site Public Contact · Contact
614-488-2745Jeffh@columbusccop.org
Aruna C. Gowda · Principal Investigator

Springfield Regional Cancer Center

Springfield, Ohio, 45504

Recruiting
Site Public Contact · Contact
614-488-2745Jeffh@columbusccop.org
Aruna C. Gowda · Principal Investigator

Springfield Regional Medical Center

Springfield, Ohio, 45504

Suspended

Mercy Health - Saint Vincent Hospital

Toledo, Ohio, 43608

Suspended

Mercy Health - Saint Anne Hospital

Toledo, Ohio, 43623

Suspended

Dayton Physicians LLC - Troy

Troy, Ohio, 45373

Suspended

Upper Valley Medical Center

Troy, Ohio, 45373

Suspended

Saint Joseph Warren Hospital

Warren, Ohio, 44484

Suspended

University of Cincinnati Cancer Center-West Chester

West Chester, Ohio, 45069

Active Not Recruiting

Saint Ann's Hospital

Westerville, Ohio, 43081

Recruiting
Site Public Contact · Contact
614-488-2745Jeffh@columbusccop.org
Aruna C. Gowda · Principal Investigator

Saint Elizabeth Youngstown Hospital

Youngstown, Ohio, 44501

Suspended

Genesis Healthcare System Cancer Care Center

Zanesville, Ohio, 43701

Recruiting
Site Public Contact · Contact
614-488-2745Jeffh@columbusccop.org
Aruna C. Gowda · Principal Investigator

Cancer Centers of Southwest Oklahoma Research

Lawton, Oklahoma, 73505

Recruiting
Site Public Contact · Contact
877-231-4440
Adanma Anji Ayanambakkam Attanathi · Principal Investigator

University of Oklahoma Health Sciences Center

Oklahoma City, Oklahoma, 73104

Recruiting
Site Public Contact · Contact
405-271-8777ou-clinical-trials@ouhsc.edu
Adanma Anji Ayanambakkam Attanathi · Principal Investigator

Mercy Hospital Oklahoma City

Oklahoma City, Oklahoma, 73120

Suspended

Oklahoma Cancer Specialists and Research Institute-Tulsa

Tulsa, Oklahoma, 74146

Suspended

Saint Alphonsus Cancer Care Center-Baker City

Baker City, Oregon, 97814

Suspended

Saint Charles Health System

Bend, Oregon, 97701

Suspended

Clackamas Radiation Oncology Center

Clackamas, Oregon, 97015

Suspended

Providence Cancer Institute Clackamas Clinic

Clackamas, Oregon, 97015

Suspended

Bay Area Hospital

Coos Bay, Oregon, 97420

Suspended

Providence Newberg Medical Center

Newberg, Oregon, 97132

Recruiting
Site Public Contact · Contact
503-215-2614CanRsrchStudies@providence.org
Alison K. Conlin · Principal Investigator

Saint Alphonsus Cancer Care Center-Ontario

Ontario, Oregon, 97914

Recruiting
Site Public Contact · Contact
406-969-6060mccinfo@mtcancer.org
Tareq Al baghdadi · Principal Investigator

Providence Willamette Falls Medical Center

Oregon City, Oregon, 97045

Recruiting
Site Public Contact · Contact
503-215-2614CanRsrchStudies@providence.org
Alison K. Conlin · Principal Investigator

Providence Portland Medical Center

Portland, Oregon, 97213

Recruiting
Site Public Contact · Contact
503-215-2614CanRsrchStudies@providence.org
Alison K. Conlin · Principal Investigator

Providence Saint Vincent Medical Center

Portland, Oregon, 97225

Recruiting
Site Public Contact · Contact
503-215-2614CanRsrchStudies@providence.org
Alison K. Conlin · Principal Investigator

Oregon Health and Science University

Portland, Oregon, 97239

Recruiting
Site Public Contact · Contact
503-494-1080trials@ohsu.edu
Christopher W. Ryan · Principal Investigator

Saint Charles Health System-Redmond

Redmond, Oregon, 97756

Suspended

Lehigh Valley Hospital-Cedar Crest

Allentown, Pennsylvania, 18103

Recruiting
Site Public Contact · Contact
610-402-9543Morgan_M.Horton@lvhn.org
Tareq Al baghdadi · Principal Investigator

Lehigh Valley Hospital - Muhlenberg

Bethlehem, Pennsylvania, 18017

Recruiting
Site Public Contact · Contact
610-402-9543Morgan_M.Horton@lvhn.org
Tareq Al baghdadi · Principal Investigator

Pocono Medical Center

East Stroudsburg, Pennsylvania, 18301

Recruiting
Site Public Contact · Contact
610-402-9543Morgan_M.Horton@lvhn.org
Tareq Al baghdadi · Principal Investigator

UPMC Hillman Cancer Center Erie

Erie, Pennsylvania, 16505

Recruiting
Site Public Contact · Contact
412-864-7716ClinicalResearchServices@upmc.edu
Leonard J. Appleman · Principal Investigator

Saint Vincent Hospital

Erie, Pennsylvania, 16544

Active Not Recruiting

UPMC Cancer Centers - Arnold Palmer Pavilion

Greensburg, Pennsylvania, 15601

Recruiting
Site Public Contact · Contact
724-838-1900
Leonard J. Appleman · Principal Investigator

Lehigh Valley Hospital-Hazleton

Hazleton, Pennsylvania, 18201

Recruiting
Site Public Contact · Contact
610-402-9543Morgan_M.Horton@lvhn.org
Tareq Al baghdadi · Principal Investigator

Jefferson Hospital

Jefferson Hills, Pennsylvania, 15025

Active Not Recruiting

Forbes Hospital

Monroeville, Pennsylvania, 15146

Active Not Recruiting

UPMC Cancer Center - Monroeville

Monroeville, Pennsylvania, 15146

Active Not Recruiting

UPMC Hillman Cancer Center - Monroeville

Monroeville, Pennsylvania, 15146

Recruiting
Site Public Contact · Contact
412-864-7716ClinicalResearchServices@upmc.edu
Leonard J. Appleman · Principal Investigator

Arnold Palmer Cancer Center Medical Oncology Norwin

N. Huntingdon, Pennsylvania, 15642

Recruiting
Site Public Contact · Contact
412-864-7716ClinicalResearchServices@upmc.edu
Leonard J. Appleman · Principal Investigator

Allegheny Valley Hospital

Natrona Heights, Pennsylvania, 15065

Active Not Recruiting

Allegheny General Hospital

Pittsburgh, Pennsylvania, 15212

Active Not Recruiting

West Penn Hospital

Pittsburgh, Pennsylvania, 15224

Active Not Recruiting

University of Pittsburgh Cancer Institute (UPCI)

Pittsburgh, Pennsylvania, 15232

Recruiting
Site Public Contact · Contact
412-647-8073
Leonard J. Appleman · Principal Investigator

UPMC-Shadyside Hospital

Pittsburgh, Pennsylvania, 15232

Active Not Recruiting

UPMC-Passavant Hospital

Pittsburgh, Pennsylvania, 15237

Recruiting
Site Public Contact · Contact
412-367-6454
Leonard J. Appleman · Principal Investigator

UPMC-Saint Clair Hospital Cancer Center

Pittsburgh, Pennsylvania, 15243

Recruiting
Site Public Contact · Contact
412-502-3920
Leonard J. Appleman · Principal Investigator

Wexford Health and Wellness Pavilion

Wexford, Pennsylvania, 15090

Active Not Recruiting

Medical University of South Carolina

Charleston, South Carolina, 29425

Recruiting
Site Public Contact · Contact
843-792-9321hcc-clinical-trials@musc.edu
Theodore S. Gourdin · Principal Investigator

University Cancer Specialists - Alcoa

Alcoa, Tennessee, 37701

Active Not Recruiting

Vanderbilt-Ingram Cancer Center Cool Springs

Franklin, Tennessee, 37067

Suspended

University of Tennessee - Knoxville

Knoxville, Tennessee, 37920

Active Not Recruiting

Vanderbilt Breast Center at One Hundred Oaks

Nashville, Tennessee, 37204

Suspended

Vanderbilt University/Ingram Cancer Center

Nashville, Tennessee, 37232

Recruiting
Site Public Contact · Contact
800-811-8480
Kerry R. Schaffer · Principal Investigator

Saint Joseph Regional Cancer Center

Bryan, Texas, 77802

Active Not Recruiting

UT Southwestern Simmons Cancer Center - RedBird

Dallas, Texas, 75237

Recruiting
Site Public Contact · Contact
214-648-7097canceranswerline@utsouthwestern.edu
Suzanne M. Cole · Principal Investigator

UT Southwestern/Simmons Cancer Center-Dallas

Dallas, Texas, 75390

Recruiting
Site Public Contact · Contact
214-648-7097canceranswerline@UTSouthwestern.edu
Suzanne M. Cole · Principal Investigator

UT Southwestern/Simmons Cancer Center-Fort Worth

Fort Worth, Texas, 76104

Recruiting
Site Public Contact · Contact
214-648-7097canceranswerline@UTSouthwestern.edu
Suzanne M. Cole · Principal Investigator

UT Southwestern Clinical Center at Richardson/Plano

Richardson, Texas, 75080

Recruiting
Site Public Contact · Contact
972-669-7044Suzanne.cole@utsouthwestern.edu
Suzanne M. Cole · Principal Investigator

Providence Regional Cancer System-Aberdeen

Aberdeen, Washington, 98520

Suspended

Overlake Medical Center

Bellevue, Washington, 98004

Suspended

PeaceHealth Saint Joseph Medical Center

Bellingham, Washington, 98225

Suspended

Highline Medical Center-Main Campus

Burien, Washington, 98166

Active Not Recruiting

Providence Regional Cancer System-Centralia

Centralia, Washington, 98531

Suspended

Swedish Cancer Institute-Edmonds

Edmonds, Washington, 98026

Suspended

Saint Elizabeth Hospital

Enumclaw, Washington, 98022

Active Not Recruiting

Providence Regional Cancer Partnership

Everett, Washington, 98201

Suspended

Saint Francis Hospital

Federal Way, Washington, 98003

Active Not Recruiting

Swedish Cancer Institute-Issaquah

Issaquah, Washington, 98029

Suspended

Kadlec Clinic Hematology and Oncology

Kennewick, Washington, 99336

Recruiting
Site Public Contact · Contact
509-783-4637research@kadlecmed.org
Alison K. Conlin · Principal Investigator

Providence Regional Cancer System-Lacey

Lacey, Washington, 98503

Suspended

Saint Clare Hospital

Lakewood, Washington, 98499

Active Not Recruiting

PeaceHealth Saint John Medical Center

Longview, Washington, 98632

Suspended

Harrison HealthPartners Hematology and Oncology-Poulsbo

Poulsbo, Washington, 98370

Active Not Recruiting

Valley Medical Center

Renton, Washington, 98055

Recruiting
Site Public Contact · Contact
425-228-3440research@valleymed.org
John A. Ellerton · Principal Investigator

Pacific Gynecology Specialists

Seattle, Washington, 98104

Suspended

Swedish Medical Center-Ballard Campus

Seattle, Washington, 98107

Suspended

Swedish Medical Center-Cherry Hill

Seattle, Washington, 98122-5711

Suspended

Swedish Medical Center-First Hill

Seattle, Washington, 98122

Suspended

PeaceHealth United General Medical Center

Sedro-Woolley, Washington, 98284

Suspended

Providence Regional Cancer System-Shelton

Shelton, Washington, 98584

Suspended

Saint Joseph Medical Center Hematology and Oncology - Silverdale

Silverdale, Washington, 98383

Active Not Recruiting

Franciscan Research Center-Northwest Medical Plaza

Tacoma, Washington, 98405

Active Not Recruiting

Northwest Medical Specialties PLLC

Tacoma, Washington, 98405

Suspended

PeaceHealth Southwest Medical Center

Vancouver, Washington, 98664

Suspended

Providence Saint Mary Regional Cancer Center

Walla Walla, Washington, 99362

Suspended

North Star Lodge Cancer Center at Yakima Valley Memorial Hospital

Yakima, Washington, 98902

Suspended

Providence Regional Cancer System-Yelm

Yelm, Washington, 98597

Suspended

Duluth Clinic Ashland

Ashland, Wisconsin, 54806

Recruiting
Site Public Contact · Contact
218-786-3308CancerTrials@EssentiaHealth.org
Bret E. Friday · Principal Investigator

Northwest Wisconsin Cancer Center

Ashland, Wisconsin, 54806

Suspended

Aurora Cancer Care-Southern Lakes VLCC

Burlington, Wisconsin, 53105

Recruiting
Site Public Contact · Contact
414-302-2304ncorp@aurora.org
Thomas J. Saphner · Principal Investigator

Aurora Saint Luke's South Shore

Cudahy, Wisconsin, 53110

Suspended

Marshfield Medical Center-EC Cancer Center

Eau Claire, Wisconsin, 54701

Recruiting
Site Public Contact · Contact
800-782-8581oncology.clinical.trials@marshfieldresearch.org
Michael Husak · Principal Investigator

Mayo Clinic Health System-Eau Claire Clinic

Eau Claire, Wisconsin, 54701

Recruiting
Site Public Contact · Contact
855-776-0015
Lance C. Pagliaro · Principal Investigator

Aurora Health Care Germantown Health Center

Germantown, Wisconsin, 53022

Recruiting
Site Public Contact · Contact
414-302-2304ncorp@aurora.org
Thomas J. Saphner · Principal Investigator

Aurora Cancer Care-Grafton

Grafton, Wisconsin, 53024

Recruiting
Site Public Contact · Contact
414-302-2304ncorp@aurora.org
Thomas J. Saphner · Principal Investigator

Aurora BayCare Medical Center

Green Bay, Wisconsin, 54311

Recruiting
Site Public Contact · Contact
414-302-2304ncorp@aurora.org
Thomas J. Saphner · Principal Investigator

Aurora Cancer Care-Kenosha South

Kenosha, Wisconsin, 53142

Recruiting
Site Public Contact · Contact
414-302-2304ncorp@aurora.org
Thomas J. Saphner · Principal Investigator

Aurora Bay Area Medical Group-Marinette

Marinette, Wisconsin, 54143

Recruiting
Site Public Contact · Contact
414-302-2304ncorp@aurora.org
Thomas J. Saphner · Principal Investigator

Marshfield Medical Center-Marshfield

Marshfield, Wisconsin, 54449

Recruiting
Site Public Contact · Contact
800-782-8581oncology.clinical.trials@marshfieldresearch.org
Michael Husak · Principal Investigator

Aurora Cancer Care-Milwaukee

Milwaukee, Wisconsin, 53209

Recruiting
Site Public Contact · Contact
414-302-2304ncorp@aurora.org
Thomas J. Saphner · Principal Investigator

Aurora Saint Luke's Medical Center

Milwaukee, Wisconsin, 53215

Recruiting
Site Public Contact · Contact
414-302-2304ncorp@aurora.org
Thomas J. Saphner · Principal Investigator

Aurora Sinai Medical Center

Milwaukee, Wisconsin, 53233

Recruiting
Site Public Contact · Contact
414-302-2304ncorp@aurora.org
Thomas J. Saphner · Principal Investigator

Marshfield Medical Center - Minocqua

Minocqua, Wisconsin, 54548

Recruiting
Site Public Contact · Contact
800-782-8581oncology.clinical.trials@marshfieldresearch.org
Michael Husak · Principal Investigator

ProHealth D N Greenwald Center

Mukwonago, Wisconsin, 53149

Recruiting
Site Public Contact · Contact
research.institute@phci.org
Timothy R. Wassenaar · Principal Investigator

Cancer Center of Western Wisconsin

New Richmond, Wisconsin, 54017

Suspended

ProHealth Oconomowoc Memorial Hospital

Oconomowoc, Wisconsin, 53066

Recruiting
Site Public Contact · Contact
262-928-7878
Timothy R. Wassenaar · Principal Investigator

Vince Lombardi Cancer Clinic - Oshkosh

Oshkosh, Wisconsin, 54904

Recruiting
Site Public Contact · Contact
414-302-2304ncorp@aurora.org
Thomas J. Saphner · Principal Investigator

Aurora Cancer Care-Racine

Racine, Wisconsin, 53406

Recruiting
Site Public Contact · Contact
414-302-2304ncorp@aurora.org
Thomas J. Saphner · Principal Investigator

Marshfield Medical Center-Rice Lake

Rice Lake, Wisconsin, 54868

Recruiting
Site Public Contact · Contact
800-782-8581oncology.clinical.trials@marshfieldresearch.org
Michael Husak · Principal Investigator

Vince Lombardi Cancer Clinic-Sheboygan

Sheboygan, Wisconsin, 53081

Recruiting
Site Public Contact · Contact
414-302-2304ncorp@aurora.org
Thomas J. Saphner · Principal Investigator

Marshfield Medical Center-River Region at Stevens Point

Stevens Point, Wisconsin, 54482

Recruiting
Site Public Contact · Contact
800-782-8581oncology.clinical.trials@marshfieldresearch.org
Michael Husak · Principal Investigator

Aurora Medical Center in Summit

Summit, Wisconsin, 53066

Recruiting
Site Public Contact · Contact
414-302-2304ncorp@aurora.org
Thomas J. Saphner · Principal Investigator

Vince Lombardi Cancer Clinic-Two Rivers

Two Rivers, Wisconsin, 54241

Recruiting
Site Public Contact · Contact
414-302-2304ncorp@aurora.org
Thomas J. Saphner · Principal Investigator

ProHealth Waukesha Memorial Hospital

Waukesha, Wisconsin, 53188

Recruiting
Site Public Contact · Contact
262-928-7632
Timothy R. Wassenaar · Principal Investigator

UW Cancer Center at ProHealth Care

Waukesha, Wisconsin, 53188

Recruiting
Site Public Contact · Contact
262-928-5539Chanda.miller@phci.org
Timothy R. Wassenaar · Principal Investigator

Aurora Cancer Care-Milwaukee West

Wauwatosa, Wisconsin, 53226

Recruiting
Site Public Contact · Contact
414-302-2304ncorp@aurora.org
Thomas J. Saphner · Principal Investigator

Aurora West Allis Medical Center

West Allis, Wisconsin, 53227

Recruiting
Site Public Contact · Contact
414-302-2304ncorp@aurora.org
Thomas J. Saphner · Principal Investigator

Marshfield Medical Center - Weston

Weston, Wisconsin, 54476

Recruiting
Site Public Contact · Contact
800-782-8581oncology.clinical.trials@marshfieldresearch.org
Michael Husak · Principal Investigator

Billings Clinic-Cody

Cody, Wyoming, 82414

Suspended

Welch Cancer Center

Sheridan, Wyoming, 82801

Suspended

References

  • Girardi DM, Niglio SA, Mortazavi A, Nadal R, Lara P, Pal SK, Saraiya B, Cordes L, Ley L, Ortiz OS, Cadena J, Diaz C, Bagheri H, Redd B, Steinberg SM, Costello R, Chan KS, Lee MJ, Lee S, Yu Y, Gurram S, Chalfin HJ, Valera V, Figg WD, Merino M, Toubaji A, Streicher H, Wright JJ, Sharon E, Parnes HL, Ning YM, Bottaro DP, Cao L, Trepel JB, Apolo AB. Cabozantinib plus Nivolumab Phase I Expansion Study in Patients with Metastatic Urothelial Carcinoma Refractory to Immune Checkpoint Inhibitor Therapy. Clin Cancer Res. 2022 Apr 1;28(7):1353-1362. doi: 10.1158/1078-0432.CCR-21-3726.(PubMed)